Pacific Biosciences of California, Inc. (PACB)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Christian O. Henry M.B.A. | President, CEO & Director | 1.1M | -- | 1968 |
| Ms. Susan G. Kim | Chief Financial Officer | 564.87k | -- | 1976 |
| Mr. Mark Van Oene | Chief Operating Officer | 772.11k | -- | 1973 |
| Mr. Jeff Eidel | Chief Commercial Officer | 435.62k | -- | 1977 |
| Dr. Stephen Turner Ph.D. | Co-Founder | 341.25k | -- | 1968 |
| Ms. Michele Farmer C.P.A. | VP & Chief Accounting Officer | -- | -- | 1980 |
| Trevin Rard | Head of Investor Relations | -- | -- | -- |
| Dr. Brett Atkins J.D., Ph.D. | General Counsel & Corporate Secretary | -- | -- | -- |
| Ms. Natalie Welch | Chief People Officer | -- | -- | -- |
| Dr. Denis Zaccarin Ph.D. | Senior Vice President of Research & Development | 510.77k | 4.34M | 1966 |
Pacific Biosciences of California, Inc.
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 796
Description
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Corporate Governance
Recent Events
- Apr 16, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 15, 2024PRE 14A: Proxy StatementsSee Full Filing
- Apr 11, 2024POSASR: Post-effective Amendment to an automatic shelf registration statement on Form S-3ASR or Form F- 3ASRSee Full Filing
- Feb 29, 2024S-8: Offering RegistrationsSee Full Filing
- Feb 15, 20248-K: Corporate Changes & Voting MattersSee Full Filing